Astria Therapeutics (NASDAQ:ATXS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Evercore ISI raised Astria Therapeutics to a strong-buy rating in a report on Wednesday, August 14th. Oppenheimer increased their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an outperform rating in a report on Tuesday, August 13th. TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a buy rating and a $35.00 price target for the company. Finally, Wedbush reiterated an outperform rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $25.20.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $11.01 on Friday. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90. The company has a market cap of $604.59 million, a P/E ratio of -4.75 and a beta of 0.71. The stock’s fifty day moving average price is $11.32 and its 200-day moving average price is $10.78.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, sell-side analysts anticipate that Astria Therapeutics will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Astria Therapeutics by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Astria Therapeutics in the fourth quarter valued at about $1,469,000. Tidal Investments LLC bought a new position in shares of Astria Therapeutics in the first quarter worth about $1,664,000. Perceptive Advisors LLC grew its position in shares of Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in Astria Therapeutics by 46.6% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock valued at $11,262,000 after purchasing an additional 466,165 shares during the period. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.